Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484 · LOTIS 5 Phase 3Active, not recruiting
- Lead sponsor
- ADC Therapeutics S.A. (Industry)
- Enrollment
- 440 (actual)
- Start date
- 16 Sep 2020
- Primary completion
- 31 Mar 2026 (actual)
- Study completion
- 30 Jun 2028
- Last update posted
- 28 Apr 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 3
Interventions
- Loncastuximab Tesirine Drug
- Rituximab Drug
- Gemcitabine Drug
- Oxaliplatin Drug
Conditions and primary outcome
- Relapsed Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
Primary outcome
Progression-free Survival (PFS) (Up to 4 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT04384484.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT04384484 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.